Figure 2. Stromal and immune scores were associated with the clinical characteristics and OS of LUAD patients. (A–L) The stromal and immune score distributions between patients with different genders (A, B), TRIM28 levels (C, D), TNM stages (E, F), T classifications (G, H), lymph node metastasis statuses (I, J) and distant metastasis statuses (K, L). (M–P) Patients were then divided into two groups according to the median stromal score or immune score. OS (M, N) and DFS (O, P) analyses were performed between the respective groups. OS, overall survival; LUAD, lung adenocarcinoma.